


I certify that this correspondence is being sent via  
First Class mail to: Assistant Commissioner for Patents,  
Washington, D.C. 20231, on March 17, 2000



PATENT

*G P1642*

*Attorney Docket No. 21511/90135*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: James Radosevich	)	
	)	
Serial No. 09/040,485	)	Examiner: Dr. Julie E. Burke
	)	
Filing Date: March 17, 1998	)	Art Unit: 1642
	)	
For A GENE ENCODING A NOVEL	)	
MARKER FOR CANCER	)	

**TRANSMITTAL LETTER**

**MAR 22 2000**

Assistant Commissioner for Patents  
Washington, D.C. 20231

**TECH CENTER 1600/2900**

Dear Sir:

Enclosed is a Information Disclosure Statement and Copies of cited material. No fees are believed necessary, however charge any additional fees which may be required, to Deposit Account No. 10-0435. A duplicate copy of this letter is enclosed.

Respectfully submitted,

*Alice O. Martin*

Alice O. Martin  
Registration No. 35,601

Barnes & Thornburg  
2600 Chase Plaza  
10 South LaSalle Street  
Chicago, Illinois 60603  
March 17, 2000

Atty. Docket No: 21511/90135

Application Serial No: 09/040,485

**PATENT APPLICATION**

**Certificate Under 37 C.F.R. 1.8(a)**

This correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner of Patents Washington, D.C. 2023 on March 17, 2000.



#  
17  
14)  
3-25-00

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Attorney Docket: 21511/90135

Serial Number: 09/040,485

Inventor: James A. Radosevich

Title: A GENE ENCODING A NOVEL  
MARKER FOR CANCER

File Date: March 17, 1998

} Group Art Number: 1642  
}  
}  
} Examiner: Dr. Julie E. Burke  
}  
}  
}  
}

**MAR 22 2000**

**TECH CENTER 1600/2900**

**SUPPLEMENTAL**  
**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This statement is filed in the application identified above pursuant to 37 C.F.R. § 1.56. No representation is intended that a complete search has been made of the prior art or that no better art references than listed below are available. A copy of each reference is provided for review by the Examiner. The filing of this Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in §1.56(b).

**PUBLICATIONS CITED IN THE INTERNATIONAL SEARCH REPORT, CLASS 'X'**

KORIOTH, F. *et al.* (1994) "Cloning and Characterization of the Human Gene Encoding Aspartyl  $\beta$ -Hydroxylase" *Gene* 150 (2):395-399

RADOSEVICH, J. A. *et al.* (1993) "Molecular - Cloning Protein Labyrinthin: V. Adenocarcinoma Tumor-Associated Antigen Detected by the Monoclonal Antibody- 44-3A6" *Clin Res* 41(3):697-8

RADOSEVICH, J.A. *et al.* (1996) "Epitope Mapping of the Adenocarcinoma Related Monoclonal Antibody 44-3A6 on Labyrinthin" *Tumor Biol* 17(1):14-15


RADOSEVICH, J.A. *et al.* (1997) "Anti-Sense Expression of Labyrinthin in A549 Cells Results In Contact Inhibition and Reduced Growth Rate" *Tumor Biol* 18(1): 12

None of the above-cited art is believed to disclose or suggest the invention recited in the claims of the above-identified application. It is therefore believed that the claimed invention is patentably distinguishable over these references.

Please charge any fees that might be due in connection with this Information Disclosure Statement to our Deposit Account No. 10-0435. An extra copy of this Information Disclosure Statement is enclosed for that purpose.

Respectfully submitted,

BARNES & THORNBURG



Alice O. Martin

Attorney Registration No. 35,601

Barnes & Thornburg  
2600 Chase Plaza  
10 South LaSalle Street  
Chicago, IL 60603  
(312) 357-1313  
March 17, 2000

AOM/lkl  
CHDS01 LKL 66588v1